Iteos Therapeutics Inc
NASDAQ:ITOS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Iteos Therapeutics Inc
NASDAQ:ITOS
|
US |
|
Z
|
Zhejiang Yasha Decoration Co Ltd
SZSE:002375
|
CN |
|
Banco Products (India) Ltd
NSE:BANCOINDIA
|
IN |
|
Firefly Neuroscience Inc
NASDAQ:AIFF
|
US |
|
Baader Bank AG
XETRA:BWB
|
DE |
|
W
|
Windward Ltd
LSE:WNWD
|
IL |
|
Credit Intelligence Ltd
ASX:CI1
|
HK |
|
Smith & Wesson Brands Inc
NASDAQ:SWBI
|
US |
|
Nanjing Hanrui Cobalt Co Ltd
SZSE:300618
|
CN |
|
Union Technologies Informatique Group SA
PAR:FPG
|
FR |
|
Mithril Resources Ltd
ASX:MTH
|
AU |
|
C
|
CK Power PCL
SET:CKP
|
TH |
|
Blue Moon Metals Inc
XTSX:MOON
|
CA |
Iteos Therapeutics Inc
iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. The company is headquartered in Watertown, Massachusetts and currently employs 94 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery and development of differentiated immuno-oncology therapeutics for patients. The firm's pipeline includes two clinical-stage programs: EOS-448 and Inupadenant (EOS-850). The Company’s lead antibody product candidate, EOS-448, is an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), an immune checkpoint with multiple mechanisms of action, which leads to immunosuppression. Its EOS-850, is designed as a selective small molecule antagonist of the adenosine A2a receptor (A2AR) in the adenosine triphosphate (ATP) adenosine pathway. The firm is conducting an open-label multi-arm Phase I/II clinical trial of inupadenant in adult cancer patients with advanced solid tumors.
iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. The company is headquartered in Watertown, Massachusetts and currently employs 94 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery and development of differentiated immuno-oncology therapeutics for patients. The firm's pipeline includes two clinical-stage programs: EOS-448 and Inupadenant (EOS-850). The Company’s lead antibody product candidate, EOS-448, is an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), an immune checkpoint with multiple mechanisms of action, which leads to immunosuppression. Its EOS-850, is designed as a selective small molecule antagonist of the adenosine A2a receptor (A2AR) in the adenosine triphosphate (ATP) adenosine pathway. The firm is conducting an open-label multi-arm Phase I/II clinical trial of inupadenant in adult cancer patients with advanced solid tumors.
GSK Partnership: iTeos received a $625 million upfront payment from GlaxoSmithKline for a partnership on EOS-448, with up to $1.45 billion in potential milestone payments.
Strong Balance Sheet: Cash and cash equivalents were $899.8 million at quarter end, supporting operations into 2026.
Revenue Surge: Quarterly revenue reached $104.3 million, driven by recognition of the GSK upfront payment; no revenue was reported in Q3 2020.
Pipeline Progress: EOS-448 and inupadenant are advancing in multiple combination trials, including new cohorts with pembrolizumab and inupadenant.
Clinical Milestones: Completed enrollment in several inupadenant clinical cohorts, with decisions made to prioritize melanoma and triple-negative breast cancer over prostate cancer.
Profitability Achieved: Net income was $69.6 million this quarter, a turnaround from a net loss a year ago.
